Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yuan-Yuan Qu, Zhisong He, Xiaodong Zhang, Xin Yao, Yu Xie, Jianming Guo, Jing Li, Bin Hu, Jiasheng Bian, Chaochao Liang, Jun Xiao, Nian-Zeng Xing, Lulin Ma, Xiaoping Zhang, Zhenhua Liu, Hui Chen, Qing Zou, Chuize Kong, Songhua Fan, Dingwei Ye
Institutions: Fudan University Shanghai Cancer Center, Peking University, Peking University First Hospital, Beijing Chao-Yang Hospital, Capital Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Hunan Cancer Hospital, Fudan University, Zhongshan Hospital, Henan Cancer Hospital, Liaoning Cancer Hospital & Institute, Shandong Tumor Hospital, Shandong First Medical University, First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Peking University Third Hospital, West China Hospital of Sichuan University, Third Affiliated Hospital of Harbin Medical University, Jiangsu Cancer Hospital, First Hospital of China Medical University, HUTCHMED (China) Limited (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162535945
Cites:
Cited by:
Related to: